The entire concept upon which the company revolves is true genius - great for all shareholders and patients down the track! We'll be sticking it up Big Pharma. Perhaps that is why it was reported recently that small biotech are guilty of NOT being totally upfront with their clinical data. And that leads me back to the results of PTX100.
Like you, I believe PTX100 to be highly significant in the scheme of things. Fwiw, Mr Eye, here is my take on PTX100 which I don't think has yet been thrashed out from a conjectural point of view:-
In last week's webinar a statement was made in reference to the other cohorts showing "indications" but was very much underplayed in the discussion. Now, we know that the TCL results are an absolute priority and why. And, I believe the expanded cohort will lead to a registration study with the high likelihood of PTX100 achieving commercialisation for TCL and PTCL as a monotherapy. It is clear that's the plan!
Now, as for the rest still in the trial... it could be that if those with solid turmors or multiple myeloma, show partial responses after a prolonged duration on the drug, then I think the company will be pursuing further trials but as a combination therapy. Afterall, Steven mentioned the safety resutls as very significant due to its attractiveness to those companies that have CarT drugs.We also know why other CarT therapies have issues and perhaps they all have less than favourable safety profiles (that I don't know for sure). But Steven did state that our safety results will make PTX100 an attractive combo drug in the existing CarT space... and that makes perfect sense. If the efficacy in relation to the other cancer types derives results, then things will get really interesting.
Also, back to 100 as a monotherapy for TCL treatment, my take is that we may or may not sell it outright... but definitely would make any acquisition and even commercial use of PTX100 conditional on pairing it with OmniCAR. Ka-Ching, Ka-Ching! Same with any chance of 100 being used as a companion drug. Let Big Pharma pay for combo Phase 2 trials if PTX100 and then make or SpyTag and SpyCatcher technololgy part of any deal on an ongoing licensing basis.
I'm loving the thought of how just 100 could pan out. In the meantime, I also have p27, the other (undisclosed) predictive biomarkers and the cell therapy enhancement stuff swirling around in my head. There's just so much to like about PTX. It seems that they have three or four arms to the business, all of which have such synergy and potential commercial viability that it is not funny!
Conviction followed by patience is all that is needed with this one, hey?
PTX Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
(20min delay)
